Navigation Links
MicroRNAs May Predict Colon Cancer Prognosis
Date:1/29/2008

This genetic material shows early promise for diagnosing, treating tumors

TUESDAY, Jan. 29 (HealthDay News) -- Knowing whether or not a particular cancer will be aggressive allows doctors to more effectively treat their patients, and a newly found class of molecules called microRNAs may help doctors do just that.

Recent research has honed in on a particular microRNA, designated miR-21, that may predict outcomes in people with colon cancer. Tumor cells with high levels of miR-21 were associated with more than twice the risk of poor survival, according to a study in the Jan. 30 issue of the Journal of the American Medical Association.

"Progress is being made that is going to eventually lead to better diagnosis and predicting prognosis," said one of the study's authors, Dr. Curtis Harris, chief of the lab of human carcinogenesis at the U.S. National Cancer Institute in Bethesda, Md. "This is a new area of research that may develop exciting new therapies, but we're very early in the discovery phase. It's only been about five years since we've known about microRNA."

Colon cancer is the third most common type of cancer in the United States, and the second-leading cause of cancer death, according to background information in the study. Surgical removal of colon cancer is currently the only curative form of therapy, according to the study.

MicroRNA molecules are an attractive research target because they help control many cell functions -- from division to proliferation to apotosis (programmed cell death). They have also been implicated in the development of cancer. MicroRNA expression has been found to be altered in other malignancies, such as leukemia, lung cancer, and pancreatic cancer, the researchers said.

The researchers theorized that microRNA production was probably altered in colon cancer as well, and if they could isolate which microRNA was associated with poorer prognosis, this could eventually help clinicians decide who needs more aggressive treatment and who would likely do well with a less aggressive regimen.

For the study, the researchers examined colon cancer tumors and non-tumorous tissue from 84 people in the United States, looking specifically at microRNA expression. To validate the U.S. findings, Hong Kong researchers also examined tumors and non-tumorous tissues from 113 Chinese adults.

The scientists found that 37 microRNAs were expressed in different levels in the tumor tissue. However, only one -- miR-21 -- was statistically significantly associated with poorer outcome. MiR-21 was also found in precancerous tissues.

Tumors that expressed high levels of miR-21 were associated with a 2.5 times increased risk of poor survival in the U.S. group, and 2.4 times increase in the risk of poor survival outcomes for the Hong Kong group.

"These are two different clinical cohorts [groups of patients] that found a single microRNA could have prognostic significance," said William Phelps, scientific program director in the research department of the American Cancer Society.

"The association was not only associated with a less favorable outcome, but was also associated with a poorer response to therapy, independent of the stage of the tumor. This seems to suggest that miR-21 is a very early marker that predicts a poorer prognosis," Phelps said.

However, both Harris and Phelps said this study's findings need to be duplicated in a larger group and in different populations before they could be applied in practice to help predict how a particular cancer might behave.

More information

To learn more about colon cancer, visit the U.S. National Library of Medicine.



SOURCES: Curtis C. Harris, M.D., chief, human carcinogenesis laboratory, National Cancer Institute, National Institutes of Health, Bethesda, Md.; William C. Phelps, Ph.D., scientific program director, research department, American Cancer Society, Atlanta; Jan. 30, 2008, Journal of the American Medical Association


'/>"/>
Copyright©2008 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. 2 microRNAs promote spread of tumor cells
2. MicroRNAs may be key to HIVs ability to hide, evade drugs, Jefferson scientists find
3. In silico modeling helps predict severity of mitochondrial disease
4. Genetic difference predicts antidepressant response
5. A simplified scoring system may predict overall CVD risk, individual CVD components risk
6. DNA Fingerprints Predict Brain Disorders
7. U.S. Preventive Medicine(R) Predicts Robust Growth Ahead
8. UQ research predicts type 2 diabetes explosion
9. Simple test accurately predicts risk of serious jaundice in newborns
10. 5 Factors Help Predict Psychosis in Children
11. Private Equitys Top Execs to Share Advice, Candid Predictions at 2008 Outlook Conference
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
MicroRNAs May Predict Colon Cancer Prognosis
(Date:4/28/2016)... , ... April 28, 2016 , ... Head Over Heels ... 9 Western Championships. The competition will be held at the University of Montana on ... gymnasts west of the Mississippi River. , In order to qualify, Varize needed to ...
(Date:4/28/2016)... ... April 28, 2016 , ... ... open availability of a new CDISC standard, Clinical Trial Registry (CTR) XML. ... This innovative standard will make it possible to build applications that generate ...
(Date:4/28/2016)... ... April 28, 2016 , ... Cosmetic Town, an online ... cosmetictown.com . The forum section was recently revamped and upgraded to allow even more ... in use across the country. , According to the senior editor of Cosmetic Town, ...
(Date:4/28/2016)... ... 2016 , ... Greener Hydroponics is now offering a large selection of Smart ... organic farmers and nurseries according to Sales Manager Joe Steele who says, “Now is ... is to offer wholesale level pricing and ultra-fast shipping for growers of any size.” ...
(Date:4/28/2016)... ... April 28, 2016 , ... In 2011, TIME magazine ... the emerging field of biomechatronics, technology that marries human physiology with electromechanics. He continues ... He is also the Founder of BionX , a leader in the field ...
Breaking Medicine News(10 mins):
(Date:4/27/2016)... 27, 2016 ... in Zürich gab Strekin AG den Start ... zur Erhaltung des Resthörvermögens von Patienten, denen ... die umfassende Phase-II-Doppelblindstudie mit Placebo-Kontrollgruppe werden momentan ... wird während der Operation direkt ins Mittelohr ...
(Date:4/27/2016)... PARIS , April 27, 2016 ... Year-Over-Year Including 42% Growth in Recurring Consumable Sales  ... Mauna Kea Technologies (Euronext: MKEA, OTCQX: MKEAY) ... today announced its sales for the first quarter ended ... business and the execution of its commercial strategy. ...
(Date:4/27/2016)... 2016 Transparency Market Research has ... - Global Industry Analysis, Size, Share, Growth, Trends, and ... global skincare devices market was valued at US$ 7,255.8 ... a CAGR of 10.1% from 2015 to 2023 to ... the full Skincare Devices Market (Treatment Device - LED Therapy ...
Breaking Medicine Technology: